LENNON VITAMINB12 INJECTION 1mL
LENNON VITAMINB12 INJECTION 10mL
SCHEDULING STATUS:
S1
PROPRIETARY NAME
(and dosage form):
i) LENNON VITAMINB12 INJECTION 1mL
ii) LENNON VITAMINB12 INJECTION 10mL
COMPOSITION
|
i) Ampoules – |
Each 1mL contains: 1000micrograms (1mg) Cyanocobalamin |
|
ii) Vials – |
Each 1mL contains: 1000micrograms (1mg) Cyanocobalamin |
|
|
1% v/v Benzyl Alcohol |
PHARMACOLOGICAL CLASSIFICATION
A22.1.4 (Vitamins - others)
PHARMACOLOGICAL ACTION
Cyanocobalamin is involved by way of its participation in the formation and metabolism of purines and pyrimidines, in the synthesis of nucleoproteins, and thus in the maintenance of normal haemopoiesis.
VitaminB12 substances bind to intrinsic factor and are then actively absorbed from the gastro-intestinal tract. Absorption is impaired in patients with an absence of intrinsic factor. Absorption from the gastro-intestinal tract can also occur by passive diffusion. VitaminB12 is extensively bound to specific plasma proteins called transcobalamins; transcobalaminII appears to be involved in the rapid transport of the cobalamins to tissues. It is stored in the liver, excreted in the bile and undergoes extensive enterohepatic recycling; part of an administered dose is excreted in the urine, most of it in the first 8hours; urinary excretion, however, accounts for only a small fraction in the reduction of total body stores acquired by dietary means. VitaminB12 diffuses across the placenta and also appears in breast milk.
After injection of cyanocobalamin a large proportion is excreted in the urine within 24hours.
INDICATIONS
Indicated in vitaminB12 deficiencies manifested by megaloblastic anaemia and neurological conditions. Pernicious anaemia and its neurological complication, subacute combined degeneration of the spinal cord. Macrocytic anaemias associated with nutritional deficiencies. Intestinal malabsorption, megaloblastosis, diet-related deficiency, post-gastrectomy. Indications for prophylaxis include strict vegetarianism, post-gastrectomy, and ileal resection and conditions of the small intestine that would predictably cause deficiency.
CONTRA-INDICATIONS
Cyanocobalamin should not be given before a diagnosis has been fully established because of the possibility of masking symptoms of subacute degeneration of the spinal cord. Cyanocobalamin should not be used to treat megaloblastic anaemia of pregnancy. Cyanocobalamin should not be administered before pernicious anaemia or folic acid deficiency has been ruled out.
WARNING:
Must not be administered intravenously.
DOSAGE AND DIRECTIONS FOR USE:
Administered intramuscularly.
In the absence of neurological involvement, cyanocobalamin may be administered in doses of 250to 1000micrograms intramuscularly on alternate days for 1to 2weeks, then 250micrograms weekly until the blood count returns to normal. Maintenance doses of 1000micrograms are administered monthly.
If there is neurological involvement, cyanocobalamin may be given in doses of 1000micrograms on alternate days and continued for as long as improvement occurs.
For the prophylaxis of anaemia associated with vitaminB12 deficiency resulting from gastrectomy or malabsorption syndromes cyanocobalamin may be given in doses of 250to 1000micrograms intramuscularly each month.
SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Allergic reactions have been reported after injection.
VitaminB12 should be given prophylactically only when there is a reasonable indication. Dietary deficiency in the strict vegetarian, the predictable malabsorption of vitaminB12 in patients who have had a gastrectomy, and certain diseases of the small intestine constitute such indications.
Administration of cyanocobalamine doses greater than 10micrograms daily, may produce a haematological response in patients with folate deficiency.
Long-term therapy with vitaminB12 must be eva luated at intervals of 6to 12months in patients who are otherwise well. If there is an additional illness or a condition that may increase the requirement for the vitamin, reassessment should be performed more frequently. It is important to monitor vitaminB12 concentrations in plasma and to obtain peripheral blood counts at intervals of 3to 6months to confirm the adequacy of therapy. Since refractoriness to therapy can develop at any time, eva luation must continue throughout the patient's life.
Serum concentrations may be decreased by concurrent administration of oral contraceptives. Blood concentrations of cyanocobalamin may be reduced if large doses of folic acid are taken continuously.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
None
IDENTIFICATION:
A dark red solution in amber glass ampoules and vials.
PRESENTATION:
|
Ampoules |
–10 x 1mL; 100 x 1mL |
|
Vials |
–10 x 10mL; 50x 10mL; 100 x 10mL |
STORAGE INSTRUCTIONS:
Protect from light. Store below 25°C.
Keep out of reach of children.
APPLICATION NUMBER:
H2413 (Act 101/1965) 1mL amber glass ampoules.
H2635 (Act 101/1965) 10mL amber glass vials.
NAME AND BUSINESS ADDRESS OF APPLICANT:
Pharmacare Limited
7 Fairclough Road
KORSTEN
PORT ELIZABETH
6020
DATE OF PUBLICATION OF THIS PACKAGE INSERT:
March, 1975
12-452/10-00
A&S PRINTERS
Updated on this site: February 2002
Current: May 2004
Source: Community Pharmacy |
